MarketCapExport financials
AdaptHealth Corp. (AHCO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AdaptHealth Corp. Financial Ratios 2025-2011 | AHCO
Brief overview of AdaptHealth Corp.'s multiples and efficiency
The comparison uses the five latest available annual observations between 2021 and 2025.
The current valuation set is P/E 15.86x (median 23.29x), EV/EBITDA 10.97x (median 32.56x), P/S 0.37x (median 0.44x). The current ratio basket stands about 29.4% below the five-year comparison base. Earnings and risk trends should explain the discount.
The inverse P/E implies an earnings yield of 6.3%. This is not a dividend yield, but current earnings relative to market price.
Capital efficiency is characterized by ROE -4.7%, ROA -1.6%, ROCE 6%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
Price, earnings and growth produce a PEG of 0.16x. A value below one indicates moderate pricing relative to expected growth.
The cash return period is stable at 16.1 days initially and 20.1 days at the end.
Overall assessment
AdaptHealth Corp.'s valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.
Annual Financial Ratios AdaptHealth Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-17.0 | 15.9 | -2.0 | 30.7 | 15.3 | -12.4 | -62.7 | 148.8 | - | - | - | - | - | - | - |
P/S |
0.4 | 0.4 | 0.4 | 0.7 | 1.0 | 1.9 | 1.8 | - | - | - | - | - | - | - | - |
EPS |
-0.5 | 0.6 | -5.1 | 0.5 | 1.1 | -3.1 | -0.9 | -0.1 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
3.89 B | 4.23 B | 4.33 B | 5.14 B | 5.42 B | 3.33 B | 1.49 B | 318 M | 166 K | - | - | - | - | - | - |
EBITDA per Share |
3.5 | 4.7 | -1.61 | 4.04 | 3.83 | 2.93 | 0.453 | -0.0395 | - | - | - | - | - | - | - |
EV/EBITDA |
8.2 | 6.7 | -20.1 | 9.5 | 11.0 | 32.6 | 38.5 | -250.8 | - | - | - | - | - | - | - |
PEG |
0.16 | 1.53 | 0.01 | - | - | 0.05 | -0.41 | 0.0 | - | - | - | - | - | - | - |
P/B |
0.8 | 0.9 | 0.9 | 1.0 | 1.2 | 5.1 | -32.2 | 1.3 | - | - | - | - | - | - | - |
P/CF |
2.0 | 2.6 | 2.8 | 5.7 | 8.7 | 10.3 | 24.1 | -189.9 | - | - | - | - | - | - | - |
ROE % |
-4.66 | 5.76 | -46.55 | 3.22 | 7.56 | -57.55 | 51.27 | 0.85 | - | - | - | - | - | - | - |
ROA % |
-1.64 | 2.02 | -15.06 | 1.33 | 2.97 | -8.91 | -2.75 | 0.82 | - | - | - | - | - | - | - |
ROCE % |
5.98 | 16.79 | -41.03 | 8.85 | 10.92 | 25.40 | 7.51 | -0.49 | - | - | - | - | - | - | - |
Current Ratio |
1.5 | 1.5 | 1.5 | 1.7 | 1.6 | 1.3 | 1.2 | 1.6 | - | - | - | - | - | - | - |
DSO |
43.8 | 44.6 | 42.7 | 44.2 | 39.5 | 43.1 | 54.2 | - | - | - | - | - | - | - | - |
DIO |
20.2 | 17.9 | 17.1 | 19.2 | 16.5 | 14.6 | 11.0 | - | - | - | - | - | - | - | - |
DPO |
43.9 | 34.9 | 30.7 | 35.9 | 39.9 | 54.9 | 65.7 | - | - | - | - | - | - | - | - |
Operating Cycle |
64.0 | 62.5 | 59.8 | 63.3 | 56.0 | 57.8 | 65.2 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
20.1 | 27.6 | 29.0 | 27.4 | 16.1 | 2.9 | -0.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios AdaptHealth Corp.
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.99 | -0.12 | - | 0.17 | 0.1 | -0.05 | - | 0.16 | 0.13 | -0.02 | - | -3.37 | 0.1 | 0.11 | - | 0.11 | 0.1 | 0.29 | - | 0.4 | 0.56 | -0.04 | - | -0.89 | 0.1 | -0.82 | - | -0.17 | -0.1 | -0.01 | - | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.65 | 0.82 | - | 1.14 | 1.23 | 0.87 | - | 1.11 | 1.03 | 1.08 | - | -2.75 | 1.07 | 0.89 | - | 1.01 | 0.96 | 0.96 | - | 1.95 | 1.36 | 0.56 | - | 1.19 | 1.14 | 0.59 | - | 2.48 | 1.99 | 1.47 | - | -0.06 | -0.03 | -0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-8.34 | 0.92 | 1.98 | 3.48 | 3.27 | 2.20 | 2.66 | -23.44 | -24.30 | -24.88 | -24.74 | -23.99 | 2.77 | 4.12 | 3.39 | 6.31 | 9.79 | 8.93 | 6.94 | -7.44 | -9.10 | -23.06 | -22.86 | 2.53 | 31.26 | 69.94 | 79.68 | 90.05 | 78.46 | 68.52 | 28.57 | 25.72 | 13.80 | 4.41 | - | - | - | -2.85 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-2.55 | 0.37 | 0.73 | 1.25 | 1.12 | 0.73 | 0.89 | -8.71 | -8.96 | -9.09 | -9.04 | -8.74 | 1.14 | 1.69 | 1.39 | 2.51 | 3.91 | 3.56 | 2.75 | -0.07 | -0.94 | -4.55 | -4.47 | -5.15 | -2.72 | -4.02 | -2.12 | -1.91 | -0.97 | -0.50 | 0.56 | 0.34 | 0.27 | 0.09 | - | - | - | -0.22 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-0.82 | 10.65 | 10.28 | 14.45 | 14.12 | 12.56 | 11.09 | -15.41 | -17.10 | -19.38 | -22.81 | -20.36 | 8.91 | 8.86 | 7.65 | 11.45 | 12.45 | 10.54 | 8.11 | 11.85 | 12.44 | 11.30 | 10.44 | -49.64 | -156.07 | -197.29 | -199.61 | -208.50 | -153.11 | -51.87 | -15.03 | -8.90 | -4.69 | -1.45 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.5 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.6 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.6 | 1.7 | 1.7 | 1.2 | 1.2 | 1.2 | 1.2 | 0.9 | 0.9 | 0.9 | 0.9 | 1.4 | 29.6 | 29.6 | 29.6 | 1.1 | 1.1 | 1.1 | 1.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
48.2 | 42.5 | - | 43.0 | 46.3 | 48.5 | - | 47.5 | 49.1 | 47.1 | - | 41.8 | 41.4 | 43.6 | - | 43.0 | 45.5 | 47.1 | - | 45.4 | 41.6 | 40.9 | - | 54.9 | 67.2 | 10.8 | - | 52.6 | 57.8 | 50.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
19.0 | 20.0 | - | 20.6 | 19.6 | 18.7 | - | 18.2 | 16.7 | 16.0 | - | 15.2 | 17.0 | 18.4 | - | 16.1 | 15.1 | 17.0 | - | 15.6 | 14.6 | 15.4 | - | 22.3 | 27.0 | 19.6 | - | 10.5 | 11.8 | 9.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
58.9 | 50.5 | - | 47.2 | 44.8 | 40.0 | - | 38.7 | 36.3 | 31.5 | - | 28.4 | 35.8 | 36.5 | - | 30.8 | 30.8 | 35.2 | - | 40.6 | 45.5 | 48.3 | - | 72.4 | 87.9 | 73.6 | - | 63.0 | 70.8 | 68.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 62.5 | - | 63.7 | 65.9 | 67.2 | - | 65.7 | 65.7 | 63.1 | - | 57.0 | 58.4 | 62.0 | - | 59.1 | 60.6 | 64.2 | - | 61.0 | 56.2 | 56.3 | - | 77.2 | 94.3 | 30.4 | - | 63.1 | 69.6 | 59.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 11.9 | - | 16.5 | 21.1 | 27.2 | - | 27.0 | 29.5 | 31.6 | - | 28.6 | 22.5 | 25.5 | - | 28.3 | 29.9 | 29.0 | - | 20.4 | 10.7 | 8.0 | - | 4.8 | 6.4 | -43.2 | - | 0.1 | -1.2 | -8.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company AdaptHealth Corp., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B |  USA |
 |
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | USA |
 |
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.53 | 2.76 % | $ 1.19 B | USA |
 |
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.35 | 0.08 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | USA |
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Apyx Medical Corporation
APYX
|
$ 2.95 | 1.37 % | $ 121 M | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.23 | 1.0 % | $ 28.2 M | USA |
 |
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | Israel |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
InspireMD
NSPR
|
$ 0.74 | 0.16 % | $ 47.6 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | USA |
 |
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | USA |
 |
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M |  Australia |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Sensus Healthcare
SRTS
|
$ 3.03 | 0.32 % | $ 49.5 M | USA |
 |
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | USA |
 |
TELA Bio
TELA
|
$ 1.3 | 0.71 % | $ 61 M | USA |
 |
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |